Carolyn Ng, Ph.D.
Carolyn Ng, Ph.D., is Managing Director at Vertex Ventures HC. At Vertex HC, Carolyn is responsible for driving venture investments across biotechnology, medical devices and health technology fields. Carolyn currently serves on the Board of Directors for Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Bicycle Therapeutics (NASDAQ: BCYC) and Nuvaira. She was also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for USD430M) and Earlens. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for USD458M). Working across the U.S., Europe and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development and syndication.
She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first-hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was a pharma strategy consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm.
Carolyn holds a Ph.D. in Cancer Molecular Biology from the National University of Singapore Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS Ph.D. Scholarship. She also holds a B.S. degree in Pharmacy with First Class Honors from the National University of Singapore, where she received the PSS Prize for Pharmaceutics awarded to the top graduating student in the class.